Company news
Lexaria Bioscience Corp. news in 2023
Lexaria Bioscience Corp.'s news releases, calls and decks from 2023, newest first.
Lexaria's Investigational New Drug Application Filing Update
December 6, 2023
Lexaria Bioscience Corp. (NASDAQ: LEXX) Expands Studies of Proprietary Platform in Multibillion-Dollar GLP-1 Drug Space
October 31, 2023
Lexaria Enters New Global Exclusive Collaboration and License Agreement with SulfoSyn
October 12, 2023
Lexaria Granted Two New Patents in Canada
October 11, 2023
Lexaria Announces Pricing of $1.6 Million Registered Direct Offering
September 28, 2023
Lexaria to Evaluate Impact of DehydraTECH on Oral Performance of GLP-1 drugs used in products such as Ozempic, Wegovy and Rybelsus, Alone or Together with DehydraTECH-CBD
September 20, 2023
Lexaria Provides Update on Investigational New Drug Application Progress
August 29, 2023
Lexaria’s Plans to Study Weight Loss and Diabetes Control in a Human Clinical Study with DehydraTECH-CBD
August 1, 2023
Lexaria Incorporates New Subsidiary for CPG Products and Updates Human Nicotine Study
July 27, 2023
Lexaria Granted Strategically Important New US Patent For DehydraTECH-Nicotine Including Oral Pouch Products
July 18, 2023
Lexaria Receives New Patents
June 19, 2023
Lexaria’s DehydraTECH-CBD Lowers Blood Glucose Levels in Diabetes Animal Study
June 15, 2023
Lexaria Appoints New Chief Financial Officer
June 11, 2023
Lexaria Discovers that DehydraTECH-CBD Treatment in Hypertension Study HYPER-H21-4 Resulted in Reduction in Pro-Inflammatory Biomarkers
May 22, 2023
Lexaria's Hormone Study Shows Significant Enhancement in Oral Estradiol Delivery
May 17, 2023
Lexaria Bioscience Announces Closing of $2.0 Million Public Offering
May 10, 2023
Lexaria Announces 2023 Annual Meeting Results
May 9, 2023
Lexaria’s Human Clinical Nicotine Study Completes Dosing as Planned
May 7, 2023
Lexaria Bioscience Announces Pricing of $2.0 Million Public Offering
May 7, 2023
Lexaria Awards CRO Contract for Upcoming U.S. Phase 1b Hypertension Study
April 23, 2023
Lexaria is Receiving Four New Patents
April 19, 2023
Lexaria Discovers Potential Novel Mechanism From Hypertension Study HYPER-H21-4
February 20, 2023